Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000919574-25-001515
Filing Date
2025-02-14
Accepted
2025-02-14 16:00:42
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 11005
2 d11606484_ex99-a.htm EX-99 6554
  Complete submission text file 0000919574-25-001515.txt   19579
Mailing Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011
Business Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011 (877) 237-5020
Neurogene Inc. (Subject) CIK: 0001404644 (see all company filings)

EIN.: 980542593 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88050 | Film No.: 25628014
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1350 AVENUE OF THE AMERICAS SUITE 2600 NEW YORK NY 10019
Business Address 1350 AVENUE OF THE AMERICAS SUITE 2600 NEW YORK NY 10019 212.300.5575
Casdin Capital, LLC (Filed by) CIK: 0001534261 (see all company filings)

EIN.: 800752351 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A